These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 3493625

  • 1. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA, Neafsey EJ, Cheng BY, Hurley-Gius K, Ung-Chhun NA, Pronger DA, Christensen MA, Hurley-Gius D.
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract] [Full Text] [Related]

  • 2. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
    Collins MA, Neafsey EJ.
    Neurosci Lett; 1985 Apr 09; 55(2):179-84. PubMed ID: 2582318
    [Abstract] [Full Text] [Related]

  • 3. Studies on the mechanism of the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Heikkila RE, Nicklas WJ, Duvoisin RC.
    Adv Neurol; 1987 Apr 09; 45():149-52. PubMed ID: 3103384
    [No Abstract] [Full Text] [Related]

  • 4. The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
    Russ H, Henning K, Eckhardt H, Przuntek H.
    Arzneimittelforschung; 1985 Apr 09; 35(2):481-2. PubMed ID: 2581589
    [Abstract] [Full Text] [Related]

  • 5. [Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
    Kucherianu VG, Kryzhanovskiĭ GN, Kudrin VS, Iurasov VV, Nikushkin EV, Zhigal'tsev IV.
    Biull Eksp Biol Med; 1999 May 09; 127(5):502-5. PubMed ID: 10399565
    [No Abstract] [Full Text] [Related]

  • 6. Tissue culture model for studying MPTP toxicity to dopamine neurons.
    Mytilineou C, Cohen G.
    Adv Neurol; 1987 May 09; 45():145-8. PubMed ID: 3493622
    [No Abstract] [Full Text] [Related]

  • 7. Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
    Rojas P, Altagracia M, Kravsov J, Rios C.
    Proc West Pharmacol Soc; 1992 May 09; 35():33-5. PubMed ID: 1502234
    [No Abstract] [Full Text] [Related]

  • 8. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
    Boireau A, Dubédat P, Bordier F, Peny C, Miquet JM, Durand G, Meunier M, Doble A.
    Neuroreport; 1994 Dec 20; 5(18):2657-60. PubMed ID: 7696626
    [Abstract] [Full Text] [Related]

  • 9. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A.
    Adv Neurol; 1987 Dec 20; 45():513-8. PubMed ID: 3493631
    [No Abstract] [Full Text] [Related]

  • 10. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K.
    Nihon Hoigaku Zasshi; 1998 Oct 20; 52(5):301-5. PubMed ID: 10077975
    [Abstract] [Full Text] [Related]

  • 11. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN, Thakar JH, Grimes JD.
    Adv Neurol; 1990 Oct 20; 53():219-23. PubMed ID: 2239461
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of the neurotoxic potential of m-methoxy-MPTP and the use of its N-ethyl analogue as a means of avoiding exposure to a possible Parkinsonism-causing agent.
    Zimmerman DM, Cantrell BE, Reel JK, Hemrick-Luecke SK, Fuller RW.
    J Med Chem; 1986 Aug 20; 29(8):1517-20. PubMed ID: 3488406
    [Abstract] [Full Text] [Related]

  • 13. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M, Rojas P, Kravzov J, Rios C.
    Proc West Pharmacol Soc; 1993 Aug 20; 36():289-91. PubMed ID: 7690973
    [No Abstract] [Full Text] [Related]

  • 14. Neuroprotective effect of arundic acid, an astrocyte-modulating agent, in mouse brain against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity.
    Himeda T, Kadoguchi N, Kamiyama Y, Kato H, Maegawa H, Araki T.
    Neuropharmacology; 2006 Mar 20; 50(3):329-44. PubMed ID: 16303147
    [Abstract] [Full Text] [Related]

  • 15. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice.
    Selley ML.
    Brain Res; 2005 Mar 10; 1037(1-2):1-6. PubMed ID: 15777746
    [Abstract] [Full Text] [Related]

  • 16. Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
    Storch A, Hwang YI, Gearhart DA, Beach JW, Neafsey EJ, Collins MA, Schwarz J.
    J Neurochem; 2004 May 10; 89(3):685-94. PubMed ID: 15086525
    [Abstract] [Full Text] [Related]

  • 17. MPTP in animal models of Parkinson's disease.
    Kopin IJ, Schoenberg DG.
    Mt Sinai J Med; 1988 Jan 10; 55(1):43-9. PubMed ID: 3126391
    [No Abstract] [Full Text] [Related]

  • 18. Parkinson-like syndrome in nonhuman primates receiving a tetrahydropyridine derivative.
    Barsoum NJ, Gough AW, Sturgess JM, de la Iglesia FA.
    Neurotoxicology; 1986 Jan 10; 7(1):119-26. PubMed ID: 3487056
    [Abstract] [Full Text] [Related]

  • 19. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ.
    Adv Neurol; 1987 Jan 10; 45():137-44. PubMed ID: 3493621
    [No Abstract] [Full Text] [Related]

  • 20. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate.
    Corsini GU, Pintus S, Chiueh CC, Weiss JF, Kopin IJ.
    Eur J Pharmacol; 1985 Dec 10; 119(1-2):127-8. PubMed ID: 3002815
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.